Breast Cancer Therapeutics Market Size By Product (Hormone Drugs, Chemotherapy Drugs, Targeted Drug Therapy), By Distribution Channel (Hospitals, Ambulatory Surgical Centres, Clinics, e-commerce, Retail Pharmacies), Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025

Published Date: Mar 2019  |  Report ID: GMI466  |  Authors: Sumant Ugalmugle

Report Format: PDF   |   Pages: 150   |   Base Year: 2018

Summary Table of Contents Industry Coverage Methodology

Industry Trends

Breast Cancer Therapeutics Market size was valued over USD 16.22 billion in 2018 and is expected to witness 9.5% CAGR from 2019 to 2025.   

Breast Cancer Therapeutics Market Overview

Get more details on this report - Request Free Sample PDF

Rising prevalence of breast cancer pertaining to factors such as prolonged exposure to endogenous oestrogens, early menarche, late age at first childbirth and late menopause will be a high impact rendering factor for the market growth. Increasing technological advances in cancer biology and launch of several diagnostic and screening programs worldwide should drive the market expansion. Growing adoption of therapeutics owing to factors such as blocking estrogenic from binding to tumour cells, risk of distant reappearance, lowering jeopardy of reappearance in the breast that had tumour and reducing risk of developing disease in another breast will propel the market progression.

Growing awareness regarding breast cancer, rising shift towards usage of western lifestyle, short breast-feeding timeframe and rising prevalence of obesity in women after menopause will stimulate the industry growth. Increasing rate of alcohol consumption in women, rising use of hormone replacement therapy (HRT) and oral birth control pills resulting in increased levels of oestrogen will boost the industry expansion over the forecast period. Growing exposure to certain carcinogens and endocrine disruptors, for example in the workplace, working night shifts results in increased risk are surging up the industry progression.

Prohibitive cost associated with the use of breast cancer therapeutics may hamper the market value. Increasing cost of early and late stage disease therapy, continuing care on a per-unit time basis, accounting for the major share of lifetime cost credited to relatively extended survival of breast cancer patients may further restrain the business growth.

The recent outbreak of COVID-19 rendered slight negative impact on breast cancer therapeutics market pertaining to rising risk of infection and spread of the virus. The COVID-19 pandemic posed unprecedented challenge for patients suffering from breast cancer. As the physicians, healthcare facilities and the system had influx of patients suffering from coronavirus, these patients were prioritized for treatment and other treatments were sidelined. Moreover, clinical evidence highlights patients suffering from cancer possess a higher risk of severe complications with COVID-19 infection. As a result, patients diagnosed with low risk early phase of breast cancers such as hormonal receptor positive early phase are advised to wait for around 6 weeks’ time period to undergo further treatment. Similarly, patients detected with pre-invasive lesions are also advised to wait for adjuvant radiotherapy till the situation normalizes. The rising infection rates of coronavirus forced the medical practitioners to address only the high-risk breast cancer patients, thereby restraining the industry value.

However, the American Society of Breast Surgeons collaborated with the Society of Surgical Oncology and developed guidelines to channelize the breast cancer care amidst the pandemic. These guidelines assisted the clinicians to treat patients with higher-risk breast cancer and reduces treatment delays. Additionally, the Dutch Society of Medical Oncology, Dutch Society of Radiotherapy and Oncology and the Dutch Society of Surgical Oncology partnered to publish treatment for continuing oncological care for breast cancer patients among others. Such initiatives will help to reduce the detrimental impact of COVID-19 pandemic on the market.

By Product

Breast Cancer Therapeutics Market Size

Get more details on this report - Request Free Sample PDF


Targeted drug therapy segment in the breast cancer therapeutics market accounted for USD 11.55 billion in 2018. It is forecast to showcase substantial growth over the coming years attributed to the associated factors such as targeting certain parts of tumour cells that allow the tumour cells to grow faster and abnormally, resulting in turn off or blockage of chemical signals. Furthermore, features such as stopping growth of new blood vessels, changing proteins, triggering immune system, and carrying toxins to the tumour cells to kill cells will foster the therapy demand during the forecast timeline.

Chemotherapy drug segment is set to observe a considerable growth at 6.6% through 2025 led by the attacking all cells that are growing quickly and inflated cost associated with the drugs resulting in financial burden. In addition, undesirable chemotherapy reactions and establishment of resistance to drugs resulting in multi-drug resistance are the major restraining factor in chemotherapy usage.

By Distribution Channel

Retail pharmacies exceeded USD 6.33 billion in 2018. Growing shift from specialty to retail pharmacies due to reimbursement variations and prolonged usage of oral formulations, particularly for targeted drug therapies will impel the market demand. Growing number of retail store and augmented investment in retail stores by retail giants in developing as well as developed economies will further boost the industry share.

Hospitals segment is predicted to expand at a CAGR of 9.5% by 2025 on account of the administration of drugs available in injectable forms in hospital settings which are reimbursed by patient’s medical benefits.

By Region

Europe Breast Cancer Therapeutics Market  

Get more details on this report - Request Free Sample PDF


U.S. breast cancer therapeutics market size was over USD 6.69 billion in 2018 driven by the growing prevalence of breast cancer and increasing R&D funding through public and private sectors. Rising elderly population, breast feeding discontinuation at an early stage and increased access to cancer care will stimulate the industry revenue. Moreover, rising demand for tumour therapeutics will strongly fuel the market expansion in the country.

Germany dominated the Europe market and captured 23% of revenue share in 2018. However, Poland breast market is estimated to grow with highest CAGR of above 10.4% by 2025.

Asia Pacific market is slated to attain a CAGR of 11.1% through 2025 impelled by the increasing incidence of disease coupled with rising acceptance of western lifestyle will influence the business expansion. Rising awareness of disease prevention, refining economic settings, and increasing adoption for technologically advanced products should drive the regional growth. 

Competitive Market Share

Some of the major players in the global market are AstraZeneca, Roche Diagnostics, Pfizer, Novartis, Eisai, Eli Lilly, Sanofi, and Celgene. Roche holds the largest revenue share owing to wide geographical presence and strong product portfolio. It is expected to dominate the market growth over the coming years. The company should face intense competition from other participants such as AstraZeneca and Pfizer during the forecast period.

Industry Background

Market is relatively competitive in nature due to broad range of pipeline products in clinical trial. Only a handful of firms offer therapeutics for breast tumour till date while others strive to introduce innovative drugs in the market over the coming years. The breast cancer industry will register a substantial expansion over next 7- 8 years.  Increasing R&D investment by manufacturers for development of novel products, mergers and acquisition, increased CSR activities to spread awareness about the breast cancer will be high impact rendering factors. Some major companies are trying to explore the lucrative markets by exploring other geographical regions.

Breast cancer therapeutics market research report includes in-depth coverage of the industry with estimates & forecast in terms of revenue in USD million from 2014 to 2025, for the following segments:

Market, by Product

  • Hormone Drugs
  • Chemotherapy Drugs
  • Targeted Drug Therapy

Market, by Distribution Channel

  • Hospitals
  • Ambulatory Surgical Centers
  • Clinics
  • e-Commerce
  • Retail Pharmacies

The above information is provided for the following regions and countries:

  • North America
    • U.S.
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • Poland
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • Malaysia
    • Indonesia
    • Thailand
  • Latin America
    • Brazil
    • Mexico
    • Argentina
  • Middle East and Africa
    • South Africa
    • UAE
    • Qatar
    • Saudi Arabia
    • Kuwait
    • Egypt

Frequently Asked Questions (FAQ) :

The market size of breast cancer therapeutics exceeded USD 16,228.2 million in 2018.
The industry share of breast cancer therapeutics is expected to witness 9.5% CAGR from 2019 to 2025.

Premium Report Details

  • Published Date: Mar 2019
  • Pages: 150
  • Tables: 80
  • Charts / Figures: 12
  • Companies covered: 9
  • Countries covered: 26

Get a report that explains COVID-19 impact on this market

Buy NowImmediate delivery available

Need a Discount? Get in touch with us for special pricing

Request Discount

 Connect with our sales team

Chat with us
We use cookies to enhance user experience. (Privacy Policy) X